| Style | Citing Format |
|---|---|
| MLA | Lahouti M, et al.. "Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study." Journal of Diabetes and Metabolic Disorders, vol. 25, no. 2, 2026, pp. -. |
| APA | Lahouti M, Esfahani E N, Heshmat R, Imani H, Abdollahpour E, Adli A, Fathzadeh K, Mardani H, Baghernia N, Azadbakht L (2026). Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study. Journal of Diabetes and Metabolic Disorders, 25(2), -. |
| Chicago | Lahouti M, Esfahani E N, Heshmat R, Imani H, Abdollahpour E, Adli A, Fathzadeh K, Mardani H, Baghernia N, Azadbakht L. "Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study." Journal of Diabetes and Metabolic Disorders 25, no. 2 (2026): -. |
| Harvard | Lahouti M et al. (2026) 'Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study', Journal of Diabetes and Metabolic Disorders, 25(2), pp. -. |
| Vancouver | Lahouti M, Esfahani E N, Heshmat R, Imani H, Abdollahpour E, Adli A, et al.. Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study. Journal of Diabetes and Metabolic Disorders. 2026;25(2):-. |
| BibTex | @article{ author = {Lahouti M and Esfahani E N and Heshmat R and Imani H and Abdollahpour E and Adli A and Fathzadeh K and Mardani H and Baghernia N and Azadbakht L}, title = {Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study}, journal = {Journal of Diabetes and Metabolic Disorders}, volume = {25}, number = {2}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Lahouti M AU - Esfahani E N AU - Heshmat R AU - Imani H AU - Abdollahpour E AU - Adli A AU - Fathzadeh K AU - Mardani H AU - Baghernia N AU - Azadbakht L TI - Dietary Macronutrient Intake and Kidney Outcomes in Patients With Type 2 Diabetes: A Cross-Sectional Study JO - Journal of Diabetes and Metabolic Disorders VL - 25 IS - 2 SP - EP - PY - 2026 ER - |